leflunomide has been researched along with Ankylosing Spondylarthritis in 8 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide is an immunosuppressive agent that acts by inhibiting pyrimidine synthesis in lymphocytes and other rapidly proliferating cells, as well as by suppressing tumor necrosis factor-alpha-induced cellular responses." | 5.35 | Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. ( Alessi, E; Barbareschi, M; Del Papa, N; Marzano, AV; Ramoni, S, 2008) |
| "In this open study of patients with active AS only those with peripheral arthritis improved significantly with leflunomide treatment." | 5.11 | Six months open label trial of leflunomide in active ankylosing spondylitis. ( Braun, J; Haibel, H; Rudwaleit, M; Sieper, J, 2005) |
| "Disease activity parameters for ankylosing spondylitis and lipid levels (total cholesterol, high-density lipoprotein cholesterol (HDLc) and triglycerides) were measured in 45 patients with ankylosing spondylitis for 6 months after starting treatment with leflunomide or placebo." | 2.72 | Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. ( de Koning, MH; Dijkmans, BA; Nurmohamed, MT; Peters, MJ; Twisk, JW; van de Stadt, RJ; van Denderen, JC; van der Horst-Bruinsma, IE; van der Paardt, M; van Halm, VP, 2006) |
| "Leflunomide is an immunosuppressive agent that acts by inhibiting pyrimidine synthesis in lymphocytes and other rapidly proliferating cells, as well as by suppressing tumor necrosis factor-alpha-induced cellular responses." | 1.35 | Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. ( Alessi, E; Barbareschi, M; Del Papa, N; Marzano, AV; Ramoni, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goh, L | 1 |
| Samanta, A | 1 |
| Chen, LA | 1 |
| Su, LH | 1 |
| Chang, YJ | 1 |
| Hsu, YL | 1 |
| Tsai, TH | 1 |
| Haibel, H | 1 |
| Rudwaleit, M | 1 |
| Braun, J | 2 |
| Sieper, J | 2 |
| van Denderen, JC | 2 |
| van der Paardt, M | 2 |
| Nurmohamed, MT | 2 |
| de Ryck, YM | 1 |
| Dijkmans, BA | 2 |
| van der Horst-Bruinsma, IE | 2 |
| Maksymowych, WP | 1 |
| van Halm, VP | 1 |
| Peters, MJ | 1 |
| Twisk, JW | 1 |
| van de Stadt, RJ | 1 |
| de Koning, MH | 1 |
| Marzano, AV | 1 |
| Ramoni, S | 1 |
| Del Papa, N | 1 |
| Barbareschi, M | 1 |
| Alessi, E | 1 |
3 reviews available for leflunomide and Ankylosing Spondylarthritis
| Article | Year |
|---|---|
A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis.
Topics: Adalimumab; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclona | 2009 |
New-onset psoriasis associated with etanercept therapy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Humans; Immunoglobulin G; Isoxazoles | 2010 |
Novel therapies for ankylosing spondylitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Biomarkers; E | 2005 |
3 trials available for leflunomide and Ankylosing Spondylarthritis
| Article | Year |
|---|---|
Six months open label trial of leflunomide in active ankylosing spondylitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Ps | 2005 |
Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis.
Topics: Adult; Aged; Antirheumatic Agents; Double-Blind Method; Female; Humans; Isoxazoles; Leflunomide; Mal | 2005 |
Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholesterol; Cholesterol, HDL; Double-Blind Me | 2006 |
2 other studies available for leflunomide and Ankylosing Spondylarthritis
| Article | Year |
|---|---|
[Spondylarthritides].
Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Mono | 2006 |
Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions.
Topics: Adjuvants, Immunologic; Adult; Antibodies, Antinuclear; Biopsy; Diagnosis, Differential; Erythema Mu | 2008 |